Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally

Fineline Cube Dec 10, 2025
Company Deals

Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal

Fineline Cube Dec 10, 2025
Company Deals

Shandong Boan Licenses US Rights for Denosumab Biosimilars to Nanjing Kingfriend in $75 Million Deal

Fineline Cube Dec 10, 2025
Company Deals

Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development

Fineline Cube Dec 10, 2025
Company Deals

Lee’s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership

Fineline Cube Dec 10, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

Innovent’s PECONDLE Meets Phase 3 IL‑23 Psoriasis Endpoints with Quarterly Dosing

Fineline Cube Dec 11, 2025
Company Drug

Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer

Fineline Cube Dec 10, 2025
Company Deals

LaNova Medicines Secures Series B Funding to Advance Oncology Pipeline

Fineline Cube Jun 29, 2022

China-based LaNova Medicines has successfully closed a Series B financing round, raising an undisclosed sum...

Company Deals

GenFleet Collaborates with BioLineRx to Develop Motixafortide for Pancreatic Cancer in China

Fineline Cube Jun 29, 2022

China-based GenFleet Therapeutics has entered into a collaboration with Israel’s BioLineRx Ltd (NASDAQ: BLRX) to...

Company Deals

Henlius and Palleon Partner on HER2-Targeted Antibody-Sialidase Fusion Protein

Fineline Cube Jun 29, 2022

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with US-based Palleon Pharmaceuticals...

Company R&D

Lundbeck Initiates TALISMAN Study on Multiple System Atrophy in China and EU

Fineline Cube Jun 28, 2022

Danish-based Lundbeck (OTCMKTS: HLUBF) has announced plans to initiate a global investigational study on multiple...

Company Deals

OCON Healthcare Partners with Bio Genuine for China Marketing Rights and Women’s Health Product Development

Fineline Cube Jun 28, 2022

Israel-based OCON Healthcare, a specialist in uterine drug delivery, has entered into a license agreement...

Company Deals

Expeclinlab Raises RMB 185 Million to Boost Clinical Mass Spectrometry Business

Fineline Cube Jun 28, 2022

Focused Photonics Inc’s (SHE: 300203) subsidiary Expeclinlab has secured RMB 185 million (USD 27.7 million)...

Company Deals

Beijing Luzhu Biotechnology Secures Series C Funding for Meningococcal Vaccine Development

Fineline Cube Jun 28, 2022

China-based Beijing Luzhu Biotechnology Co., Ltd has reportedly secured an undisclosed amount in a Series...

Company Drug

Eli Lilly’s Donanemab Receives Tacit Approval for Alzheimer’s Clinical Trial in China

Fineline Cube Jun 28, 2022

The Center for Drug Evaluation (CDE) website indicates that US major Eli Lilly’s (NYSE: LLY)...

Company Deals R&D

Hainan Lecheng Partners with Fosun Pharma on Innovative Medical Devices and Diagnostics

Fineline Cube Jun 28, 2022

The Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration has formed a partnership with...

Company Drug

Recbio’s R520A mRNA COVID-19 Vaccine Receives Clinical Approval in the Philippines

Fineline Cube Jun 28, 2022

China-based Jiangsu Recbio Technology Co., Ltd has announced receiving clinical trial approval from the Food...

Company Drug

Pfizer’s Besponsa First Prescribed in China for Leukemia Treatment

Fineline Cube Jun 28, 2022

US major Pfizer (NYSE: PFE) has announced the first prescriptions for its leukemia therapy Besponsa...

Company

Kelun Pharmaceutical Receives USD 30 Million from MSD for Licensing Deal

Fineline Cube Jun 28, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced receiving USD 30 million from...

Company Deals

ImmuneOnco Biopharmaceuticals Files for HKSE IPO with Comprehensive Tumor Immunotherapy Pipeline

Fineline Cube Jun 28, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has submitted an initial public offering (IPO) filing to the...

Company Drug

Clover Biopharmaceuticals’ SCB-2019 COVID-19 Vaccine Shows Strong Immune Response in Third Shot Study

Fineline Cube Jun 28, 2022

China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has published clinical data for its COVID-19 vaccine candidate...

Company Drug

Harbour BioMed Receives FDA Approval for HBM7008 Clinical Trials

Fineline Cube Jun 28, 2022

China-based Harbour BioMed (HKG: 2142) has announced receiving clinical trial approval from the US FDA...

Drug

Sinovac Biotech’s CoronaVac Receives Conditional Registration from South African Regulator

Fineline Cube Jun 28, 2022

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced that the South African Health Products Regulatory...

Company Medical Device

Joysbio Develops Rapid Test for SARS-CoV-2 Omicron Subvariants BA.4 and BA.5

Fineline Cube Jun 28, 2022

China-based Joysbio (Tianjin) Biotechnology Co., Ltd. has developed a rapid test to diagnose the latest...

Company Deals

Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma

Fineline Cube Jun 28, 2022

China-based Antengene Corporation Ltd (HKG: 6996) has announced a clinical trial collaboration with BeiGene Inc....

Policy / Regulatory

7th National VBP Round Venue Moved to Nanjing from Shanghai

Fineline Cube Jun 27, 2022

In a departure from previous practice, the 7th national volume-based procurement (VBP) round will not...

Company Drug

Sino Biopharmaceutical’s TQ-B3101 Accepted by NMPA for ROS1+ NSCLC Treatment

Fineline Cube Jun 27, 2022

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the National Medical Products Administration (NMPA)...

Posts pagination

1 … 587 588 589 … 596

Recent updates

  • Innovent’s PECONDLE Meets Phase 3 IL‑23 Psoriasis Endpoints with Quarterly Dosing
  • D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally
  • Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal
  • Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer
  • Innovent Doses First Patient in Phase 1 Trial of IBI3011, China’s First Anti‑IL‑1RAP Antibody for Gout Flares
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Innovent’s PECONDLE Meets Phase 3 IL‑23 Psoriasis Endpoints with Quarterly Dosing

Company Deals

D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally

Company Deals

Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal

Company Drug

Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.